{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:42:44Z","timestamp":1780926164505,"version":"3.54.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Suzhou Minsheng Science and Technology","award":["SYS2020094"],"award-info":[{"award-number":["SYS2020094"]}]},{"name":"Project of Jiangsu Health Development Research Center","award":["JSHD2022067"],"award-info":[{"award-number":["JSHD2022067"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ovarian cancer (OC), with its high mortality rate among gynecological cancers, is often diagnosed late due to the lack of early diagnostic symptoms and biomarkers. The tumor immune microenvironment has become a focal point in cancer diagnostic and therapeutic research. Among these, B7-H4, a checkpoint protein, plays a crucial role in immune regulation and tumor suppression, contributing to immune evasion within the tumor microenvironment. This study aims to identify the concentration of soluble B7-H4(sB7-H4) in the plasma of patients with OC and to evaluate its clinical significance. Through a comprehensive analysis involving enzyme-linked immunosorbent assay, immunohistochemistry, and multicolor immunofluorescence, we quantified sB7-H4 levels in patient plasma and ascites, correlating these findings with tissue expression and clinical outcomes. Results indicated a strong association between high sB7-H4 levels and advanced disease, surgical outcomes, lymphatic metastasis, and platinum resistance. When compared with traditional biomarkers CA125 and HE4, sB7-H4, especially in conjunction with these markers, enhances the diagnostic accuracy for epithelial ovarian cancer (EOC), offering insights into disease progression and therapeutic efficacy. This comprehensive analysis suggests that sB7-H4 is a promising biomarker for EOC, providing valuable insights into diagnosis, stage differentiation, treatment effectiveness, and prognosis.<\/jats:p>","DOI":"10.1093\/cei\/uxae084","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T14:34:09Z","timestamp":1728311649000},"source":"Crossref","is-referenced-by-count":9,"title":["sB7-H4 is a diagnostic biomarker in epithelial ovarian cancer and correlates to platinum resistance"],"prefix":"10.1093","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4023-991X","authenticated-orcid":false,"given":"Ying","family":"Zhou","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Soochow University Department of Obstetrics and Gynecology, , Jiangsu ,","place":["China"]},{"name":"Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University , Jiangsu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingluan","family":"Tian","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University Department of Neurology, , Suzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University , Jiangsu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansi","family":"Liang","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University , Jiangsu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youguo","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University Department of Obstetrics and Gynecology, , Jiangsu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University Department of Obstetrics and Gynecology, , Jiangsu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzheng","family":"Gu","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University , Jiangsu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"2025070813215688400_CIT0001","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1158\/1078-0432.ccr-15-2440","article-title":"Molecular pathways: evaluating the potential for B7-H4 as an immunoregulatory","volume":"23","author":"MacGregor","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025070813215688400_CIT0002","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1074-7613(03)00152-3","article-title":"B7-H4, a molecule of the B7 family, negatively regulates T cell immunity","volume":"18","author":"Sica","year":"2022","journal-title":"Immunity"},{"key":"2025070813215688400_CIT0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13048-022-01076-z","article-title":"The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial\u2013mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma","volume":"16","author":"Hwang","year":"2023","journal-title":"J Ovarian Res"},{"key":"2025070813215688400_CIT0004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2021.04.003","article-title":"Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas","volume":"113","author":"Niu","year":"2021","journal-title":"Hum Pathol"},{"key":"2025070813215688400_CIT0005","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.humpath.2018.05.021","article-title":"B7H4 is associated with stemness and cancer progression in esophageal squamous cell carcinoma","volume":"80","author":"Piao","year":"2018","journal-title":"Hum Pathol"},{"key":"2025070813215688400_CIT0006","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/imr.12530","article-title":"Potential targeting of B7-H4 for the treatment of cancer","volume":"276","author":"Podojil","year":"2017","journal-title":"Immunol Rev"},{"key":"2025070813215688400_CIT0007","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1038\/s41598-024-56681-3","article-title":"Interferon-\u03b3 in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells","volume":"14","author":"Jing","year":"2024","journal-title":"Sci Rep"},{"key":"2025070813215688400_CIT0008","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.4049\/jimmunol.1202439","article-title":"Host b7x promotes pulmonary metastasis of breast cancer","volume":"190","author":"Abadi","year":"2013","journal-title":"J Immunol"},{"key":"2025070813215688400_CIT0009","doi-asserted-by":"publisher","first-page":"72242","DOI":"10.18632\/oncotarget.12665","article-title":"Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases","volume":"7","author":"Qian","year":"2016","journal-title":"Oncotarget"},{"key":"2025070813215688400_CIT0010","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2147\/OTT.S48085","article-title":"Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors","volume":"6","author":"Li","year":"2013","journal-title":"OncoTargets and therapy"},{"key":"2025070813215688400_CIT0011","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/IGC.0b013e3181ad0fa2","article-title":"B7-H4 expression promotes tumorigenesis in ovarian cancer","volume":"19","author":"Cheng","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"2025070813215688400_CIT0012","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-18-2202","article-title":"Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment","volume":"25","author":"Tulotta","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025070813215688400_CIT0013","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN Guidelines\u00ae insights: ovarian cancer, version 3.2022","volume":"20","author":"Armstrong","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2025070813215688400_CIT0014","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41467-020-17046-2","article-title":"Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients","volume":"11","author":"N\u00fa\u00f1ez","year":"2020","journal-title":"Nat Commun"},{"key":"2025070813215688400_CIT0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ygyno.2019.12.043","article-title":"A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer","volume":"156","author":"Monk","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2025070813215688400_CIT0016","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2025070813215688400_CIT0017","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ygyno.2016.06.013","article-title":"FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited","volume":"142","author":"Ataseven","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2025070813215688400_CIT0018","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Original reports-gynecologic oncology-survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"JCO"},{"key":"2025070813215688400_CIT0019","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"2025070813215688400_CIT0020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ygyno.2009.10.087","article-title":"Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer","volume":"116","author":"Andersen","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2025070813215688400_CIT0021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"2025070813215688400_CIT0022","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1158\/1078-0432.CCR-15-0858","article-title":"B 7-H4(B7x)-mediated cross-talk between glioma-initiating cells and macrophages via the IL6\/JAK\/STAT3 pathway lead to poor prognosis in glioma patients","volume":"22","author":"Yao","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025070813215688400_CIT0023","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3390\/cells12060832","article-title":"Prognostic role of soluble and extracellular vesicle-associated PD-L1, B7-H3 and B7-H4 in non-small cell lung cancer patients treated with immune checkpoint inhibitors","volume":"12","author":"Genova","year":"2023","journal-title":"Cells"},{"key":"2025070813215688400_CIT0024","doi-asserted-by":"publisher","first-page":"e0199719","DOI":"10.1371\/journal.pone.0199719","article-title":"Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma","volume":"13","author":"Azuma","year":"2018","journal-title":"PLoS One"},{"key":"2025070813215688400_CIT0025","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1166\/jbn.2019.2741","article-title":"Role of B7-H4 in the progression and prognosis of cervical inflammation to cancer after human papilloma virus infection","volume":"15","author":"Qiu","year":"2019","journal-title":"J Biomed Nanotechnol"},{"key":"2025070813215688400_CIT0026","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13048-023-01102-8","article-title":"Prognostic significance and risk factors for pelvic and para-aortic lymph node metastasis in type I and type II ovarian cancer: a large population-based database analysis","volume":"16","author":"Yu","year":"2023","journal-title":"J Ovarian Res"},{"key":"2025070813215688400_CIT0027","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1200\/jco.2017.35.15_suppl.5500","article-title":"LION: lymphadenectomy in ovarian neoplasms\u2014a prospective randomized AG O study group led gynecologic cancer intergroup trial","volume":"35","author":"Harter","year":"2017","journal-title":"JCO"},{"key":"2025070813215688400_CIT0028","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.4049\/jimmunol.1202439","article-title":"Host B7x promotes pulmonary metastasis of breast cancer","volume":"190","author":"Abadi","year":"2013","journal-title":"J. Immun."},{"key":"2025070813215688400_CIT0029","doi-asserted-by":"crossref","first-page":"82740","DOI":"10.18632\/oncotarget.21098","article-title":"Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells","volume":"8","author":"Ohaegbulam","year":"2017","journal-title":"Oncotarget"},{"key":"2025070813215688400_CIT0030","doi-asserted-by":"publisher","first-page":"188950","DOI":"10.1016\/j.bbcan.2023.188950","article-title":"Lymphatic vasculature in ovarian cancer","volume":"1878","author":"Pal","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"2025070813215688400_CIT0031","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u0131\u0301n","year":"2023","journal-title":"Ann Oncol"},{"key":"2025070813215688400_CIT0032","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","article-title":"The systemic treatment of recurrent ovarian cancer revisited","volume":"32","author":"Baert","year":"2021","journal-title":"Ann Oncol"},{"key":"2025070813215688400_CIT0033","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol Oncol"},{"key":"2025070813215688400_CIT0034","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025070813215688400_CIT0035","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1078-0432.ccr-23-1079","article-title":"A B7-H4\u2013targeting antibody\u2013drug conjugate shows antitumor activity in PARPi and platinum-resistant cancers with B7-H4 Expression","volume":"30","author":"Gitto","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025070813215688400_CIT0036","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxae084\/60778524\/uxae084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/219\/1\/uxae084\/60778524\/uxae084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/219\/1\/uxae084\/60778524\/uxae084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T17:22:08Z","timestamp":1751995328000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/doi\/10.1093\/cei\/uxae084\/7814874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxae084","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2024,10,7]]},"article-number":"uxae084"}}